SEC. 103. Development of strategy to accelerate research and development of non-intrusive, advanced inspection technologies to detect illicit synthetic drugs.
(a) Defined term.—In this section, the term “appropriate congressional committees” means—

(1) the Committee on Commerce, Science, and Transportation of the Senate;

(2) the Committee on Homeland Security and Governmental Affairs of the Senate;

(3) the Committee on Finance of the Senate;

(4) the Committee on the Judiciary of the Senate;

(5) the Committee on Energy and Commerce of the House of Representatives;

(6) the Committee on Homeland Security of the House of Representatives;

(7) the Committee on Financial Services of the House of Representatives; and

(8) the Committee on the Judiciary of the House of Representatives.

(b) In general.—The Director of the Office of Science and Technology Policy and the Director of the Office of National Drug Control Policy, in consultation and coordination with the Director of the National Science Foundation, the Secretary of Commerce (acting through the Director of the National Institute of Standards and Technology), the Secretary of Energy, the Secretary of Homeland Security, the Administrator of the Transportation Security Administration, and the Attorney General, shall—

(1) develop a joint strategy to accelerate research and development and deployment of non-intrusive, advanced inspection technologies and other advanced inspection technologies to detect illicit synthetic drugs, such as artificial intelligence and quantum hybrid computing and integration of multiple data sources; and

(2) not later than 2 years after the date of the enactment of this Act, submit a report on such strategy to the appropriate congressional committees.


